The IPO provides Latigo with substantial capital to fund its pipeline, but as a newly public clinical-stage biotech with no revenue, the stock will trade on pipeline catalysts and cash burn rate. Monitor upcoming quarterly filings for R&D spending and pipeline progress. The insider buy of $2.5M in the prior 30 days suggests management confidence ahead of the IPO.
Price Chart
Executive Summary
Latigo Biotherapeutics completed its IPO on August 10, 2026, selling 19,200,000 shares at $18.00 per share for gross proceeds of approximately $345.6 million. In connection with the IPO, the company filed an amended and restated certificate of incorporation and adopted amended and restated bylaws, both effective immediately prior to the closing. The IPO provides a substantial cash infusion for a clinical-stage biotech, but the filing is a routine post-IPO administrative update with no new operational or financial performance data.
Key Facts
- IPO closed on August 10, 2026 with 19,200,000 shares sold at $18.00 per share
- Gross proceeds from the IPO were approximately $345.6 million before underwriting discounts and commissions
- Amended and restated certificate of incorporation and bylaws filed effective immediately prior to IPO closing
- Authorized capital stock increased to 999,999,999 shares of common stock and 10,000,000 shares of preferred stock
- Board classified into three classes with staggered three-year terms; directors can only be removed for cause with 66-2/3% supermajority vote
- Stockholder action by written consent prohibited unless approved by all directors; special meetings can only be called by board chair, CEO, or majority of directors
- Exclusive forum provisions for derivative claims (Delaware Chancery) and Securities Act claims (federal district court)
- Supermajority 66-2/3% vote required to amend certain governance provisions
Financial Impact
IPO gross proceeds of approximately $345.6 million raised, providing significant cash runway for a clinical-stage biotech
Risk Factors
- Clinical-stage biotech with no approved products or revenue; pipeline failure risk is high
- Post-IPO dilution of 19.2M shares may pressure stock in near term as lock-up expiration approaches
- Governance provisions (classified board, supermajority vote requirements, prohibition on written consent) may deter activist investors or takeover interest
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-342321 |
| Document: d170764d8k.htm | 0001193125-26-342321 |
| Document: 0001193125-26-342321-index-headers.html | 0001193125-26-342321 |
| Document: 0001193125-26-342321-index.html | 0001193125-26-342321 |
| Document: 0001193125-26-342321.txt | 0001193125-26-342321 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 7w ago | Press Release | $23.04 $23.73 | ▲ +2.99% | ▲ +3.54% | $15.48 (−32.83%) |
Aug 12, 2026 10w ago | 3 | $19.38 $20.06 | ▲ +3.54% | ▲ +2.84% | $15.48 (−20.13%) |
Aug 10, 2026 10w ago | Insider Cluster | $18.52 $19.38 | ▲ +4.62% | ▲ +4.37% | $15.48 (−16.44%) |
Aug 10, 2026 10w ago | Insider Cluster | $18.52 $19.38 | ▲ +4.62% | ▲ +4.37% | $15.48 (−16.44%) |
Aug 10, 2026 10w ago | Insider Cluster | $18.52 $19.38 | ▲ +4.62% | ▲ +4.37% | $15.48 (−16.44%) |
Aug 10, 2026 10w ago | Insider Cluster | $18.52 $19.38 | ▲ +4.62% | ▲ +4.37% | $15.48 (−16.44%) |
Aug 10, 2026 10w ago | 8-K | $18.52 $19.38 | ▲ +4.62% | ▲ +4.37% | $15.48 (−16.44%) |
Aug 7, 2026 11w ago | EFFECT | $18.25 $18.56 | ▲ +1.70% | ▲ +1.73% | $15.48 (−15.21%) |
Aug 6, 2026 11w ago | 3 | $18.25 $18.56 | ▲ +1.70% | ▲ +1.73% | $15.48 (−15.21%) |
Aug 6, 2026 11w ago | 3 | $18.25 $18.56 | ▲ +1.70% | ▲ +1.73% | $15.48 (−15.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers